MedTrace Logo

P3 Study in Acne Comparing Once Daily SB204 and Vehicle

NCT02672332 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1307

Last updated 2023-07-24

Study results available
· View outcomes & findings →

Summary

This is a 12 week, multi-center, double-blinded, randomized, vehicle-controlled, parallel group, study to be conducted in approximately 1300 subjects with acne vulgaris in the US.

Conditions

  • Acne Vulgaris

Interventions

DRUG

SB204 4%

Once daily

DRUG

Vehicle Gel

Placebo comparator

Sponsors & Collaborators

  • Chiltern International Inc.

    collaborator INDUSTRY

  • Novan, Inc.

    lead INDUSTRY

Principal Investigators

  • Joyce Rico, MD · Novan, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
9 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-22
Primary Completion
2016-12-31
Completion
2016-12-21

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02672332 on ClinicalTrials.gov